Using in vivo CML models in chronic phase and blast crisis (13) suggested that Msi2-Numb can be a novel target for leukemia treatment since it can control CML stem cells differentiation and apoptosis (38). The gene discussed is MSI2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.